U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Science & Research
  3. Science and Research Special Topics
  4. Clinical Trials and Human Subject Protection
  5. Investigational New Drug Applications and New Drug Applications (9/8/1995)
  1. Clinical Trials and Human Subject Protection

Investigational New Drug Applications and New Drug Applications (9/8/1995)

[Federal Register: September 8, 1995 (Volume 60, Number 174)]
[Proposed Rules] 
[Page 46794-46797]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr08se95-24]

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
21 CFR Parts 312 and 314
[Docket No. 95N-0010]

Investigational New Drug Applications and New Drug Applications
AGENCY: Food and Drug Administration, HHS.
ACTION: Proposed rule.

SUMMARY: The Food and Drug Administration (FDA) is proposing to amend its regulations pertaining to investigational new drug applications (IND's) and new drug applications (NDA's). The proposed rule would clearly define in the NDA format and content requirements the need to present effectiveness and safety data for important demographic subgroups, specifically sex, age, and racial subgroups. The rule would codify expectations that FDA has previously described in guidance. The proposed amendments would also require IND sponsors of drugs, including biological products, to characterize, in their annual reports, the number of subjects in a clinical study according to age group, sex, and race. The proposed rule does not address the requirements for the conduct of clinical studies and would not require sponsors to conduct any more studies than they have already conducted. It also would not require the inclusion of particular numbers of individuals from specific subgroups in any study or overall. The rule refers only to the presentation of data already collected. The scope of this proposal does not extend to requiring additional studies or data.

TEXT: https://www.govinfo.gov/content/pkg/FR-1995-09-08/pdf/95-22297.pdf 

Back to Top